Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Irvine
Revolution Medicines, Inc.
Seagen Inc.
Alterome Therapeutics, Inc.